Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Crinetics Pharma, AstraZeneca, Novartis, Sparrow Pharma, Corcept Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Cushing's Syndrome pipeline constitutes 4+ key companies continuously working towards developing 4+ Cushing's Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Cushing's Syndrome Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cushing's Syndrome Market.

The Cushing's Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cushing's Syndrome Pipeline Report: https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Cushing's Syndrome treatment therapies with a considerable amount of success over the years.
• Cushing's Syndrome companies working in the treatment market are Crinetics Pharmaceuticals, AstraZeneca, Novartis, Sparrow Pharmaceuticals, Corcept Therapeutics, RECORDATI GROUP, Cortendo AB, HRA Pharma, Cortendo AB, Sparrow Pharmaceuticals, and others, are developing therapies for the Cushing's Syndrome treatment
• Emerging Cushing's Syndrome therapies such as - CRN-04894, AZD4017, SOM230, SPI 62, Relacorilant, osilodrostat, Levoketconazole, metyrapone, evoketconazole, SPI-62, and others are expected to have a significant impact on the Cushing's Syndrome market in the coming years.
• In February 2025, Sterotherapeutics, a US-based clinical-stage company, initiated a Phase II clinical trial for its investigational drug ST-002 to treat Cushing's Syndrome, a rare endocrine disorder. The study aims to evaluate the drug's efficacy, safety, and tolerability in affected individuals and will be conducted across multiple clinical sites in Europe.
• In December 2024, Corcept Therapeutics, a US-based biotechnology company, announced positive long-term results from its Phase III study evaluating relacorilant for endogenous hypercortisolism (Cushing's syndrome). The treatment demonstrated sustained cardiometabolic benefits and was well tolerated for up to six years. The open-label extension study included 116 participants who had previously completed the GRACE or GRADIENT studies or a Phase II clinical trial in hypercortisolism.
• In October 2024, Sparrow Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing targeted therapies for unmet needs in endocrinology and immunology, announced the completion of the Phase 2 RESCUE trial evaluating clofutriben, a potent and selective HSD-1 inhibitor, for endogenous Cushing's syndrome. All eligible patients who completed the trial chose to continue treatment under an open-label extension (OLE) protocol.

Cushing's Syndrome Overview
Cushing's syndrome is a hormonal disorder caused by prolonged exposure to high levels of cortisol, a hormone produced by the adrenal glands. It can result from various factors, including excessive use of corticosteroid medications or overproduction of cortisol by the adrenal glands or tumors elsewhere in the body.

Get a Free Sample PDF Report to know more about Cushing's Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Cushing's Syndrome Drugs Under Different Phases of Clinical Development Include:
• CRN-04894: Crinetics Pharmaceuticals
• AZD4017: AstraZeneca
• SPI 62: Sparrow Pharmaceuticals
• Relacorilant: Corcept Therapeutics
• SPI-62: Sparrow Pharmaceuticals

Route of Administration
Cushing's Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Cushing's Syndrome Pipeline Therapeutics Assessment
• Cushing's Syndrome Assessment by Product Type
• Cushing's Syndrome By Stage and Product Type
• Cushing's Syndrome Assessment by Route of Administration
• Cushing's Syndrome By Stage and Route of Administration
• Cushing's Syndrome Assessment by Molecule Type
• Cushing's Syndrome by Stage and Molecule Type

DelveInsight's Cushing's Syndrome Report covers around 4+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Cushing's Syndrome product details are provided in the report. Download the Cushing's Syndrome pipeline report to learn more about the emerging Cushing's Syndrome therapies
https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cushing's Syndrome Pipeline Analysis:
The Cushing's Syndrome pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Cushing's Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cushing's Syndrome Treatment.
• Cushing's Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cushing's Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cushing's Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cushing's Syndrome drugs and therapies
https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cushing's Syndrome Pipeline Market Drivers
• Entrance of novel therapies will drive Cushing's syndrome market growth, increase in the number of research and development activities are some of the important factors that are fueling the Cushing's Syndrome Market.

Cushing's Syndrome Pipeline Market Barriers
• However, high cost associated treatment, strict regulatory policies and lack of awareness among people and other factors are creating obstacles in the Cushing's Syndrome Market growth.

Scope of Cushing's Syndrome Pipeline Drug Insight
• Coverage: Global
• Key Cushing's Syndrome Companies: Crinetics Pharmaceuticals, AstraZeneca, Novartis, Sparrow Pharmaceuticals, Corcept Therapeutics, RECORDATI GROUP, Cortendo AB, HRA Pharma, Cortendo AB, Sparrow Pharmaceuticals, and others
• Key Cushing's Syndrome Therapies: CRN-04894, AZD4017, SOM230, SPI 62, Relacorilant, osilodrostat, Levoketconazole, metyrapone, evoketconazole, SPI-62, and others
• Cushing's Syndrome Therapeutic Assessment: Cushing's Syndrome current marketed and Cushing's Syndrome emerging therapies
• Cushing's Syndrome Market Dynamics: Cushing's Syndrome market drivers and Cushing's Syndrome market barriers

Request for Sample PDF Report for Cushing's Syndrome Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Cushing's Syndrome Report Introduction
2 Cushing's Syndrome Executive Summary
3 Cushing's Syndrome Overview
4 Cushing's Syndrome- Analytical Perspective In-depth Commercial Assessment
5 Cushing's Syndrome Pipeline Therapeutics
6 Cushing's Syndrome Late Stage Products (Phase II/III)
7 Cushing's Syndrome Mid Stage Products (Phase II)
8 Cushing's Syndrome Early Stage Products (Phase I)
9 Cushing's Syndrome Preclinical Stage Products
10 Cushing's Syndrome Therapeutics Assessment
11 Cushing's Syndrome Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Cushing's Syndrome Key Companies
14 Cushing's Syndrome Key Products
15 Cushing's Syndrome Unmet Needs
16 Cushing's Syndrome Market Drivers and Barriers
17 Cushing's Syndrome Future Perspectives and Conclusion
18 Cushing's Syndrome Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Cushing's Syndrome Market https://www.delveinsight.com/report-store/cushings-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Cushing's Syndrome-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Cushing's Syndrome Epidemiology https://www.delveinsight.com/report-store/cushings-syndrome-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Cushing's Syndrome Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Mammography Devices Market: https://www.delveinsight.com/report-store/mammography-devices-market
• Global Kinase Inhibitor Market: https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market-insight
• Nerve Repair And Regeneration Devices- Market Insights: https://www.delveinsight.com/report-store/nerve-repair-and-regeneration-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Diabetic Wound Market: https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.